Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push Read more →
Merck and Sarah Cannon team up to boost oncology trial efficiency Read more →
Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss Read more →
« All Events
February 4, 2025 @ 11:30 am
Presentations from the Olink team on the value of combining genomic and proteomic data for the best insights into human disease and development of new therapeutics, and more. After, enjoy lunch and networking.